Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas, Inc. - Common Stock
(NQ:
ARVN
)
6.560
-0.340 (-4.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arvinas, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
April 04, 2025
Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for Parkinson's and PSP treatment.
Via
Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Month
March 26, 2025
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
March 12, 2025
Via
Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
March 12, 2025
Via
Benzinga
Tuesday's session: top gainers and losers
March 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
These Analysts Revise Their Forecasts On Arvinas After Q4 Results
February 12, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Arvinas
February 07, 2025
Via
Benzinga
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
March 11, 2025
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Via
Benzinga
Gapping stocks in Tuesday's session
March 11, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Crude Oil Gains 1%; Ciena Earnings Top Views
March 11, 2025
Via
Benzinga
Exposures
Fossil Fuels
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
March 11, 2025
The companies are looking to use protein degradation to take on some forms of breast cancer.
Via
Investor's Business Daily
Stay updated with the stocks that are on the move in today's pre-market session.
March 11, 2025
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
Demystifying Arvinas: Insights From 5 Analyst Reviews
December 11, 2024
Via
Benzinga
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results
March 11, 2025
Via
Benzinga
Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday
February 12, 2025
Via
Benzinga
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
February 11, 2025
U.S.
Via
Benzinga
Unveiling 4 Analyst Insights On Arvinas
November 20, 2024
Via
Benzinga
What's Next: Arvinas's Earnings Preview
October 29, 2024
Via
Benzinga
Earnings Scheduled For February 11, 2025
February 11, 2025
Via
Benzinga
Critical Insights From Arvinas Analyst Ratings: What You Need To Know
September 09, 2024
Via
Benzinga
The Latest Analyst Ratings For Arvinas
July 31, 2024
Via
Benzinga
Analyst Ratings For Arvinas
May 17, 2024
Via
Benzinga
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
January 21, 2025
Via
The Motley Fool
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
December 10, 2024
Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and tolerable safety for advanced breast cancer therapy.
Via
Benzinga
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Biotech Arvinas Stock Earns 82 RS Rating
July 17, 2024
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.
Via
Investor's Business Daily
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 16, 2024
Via
Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
July 16, 2024
Via
Benzinga
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
June 14, 2024
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist.
Via
Talk Markets
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
May 16, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.